MARKET

AMPH

AMPH

Amphastar Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.71
+0.03
+0.16%
After Hours: 18.71 0 0.00% 16:00 09/24 EDT
OPEN
18.63
PREV CLOSE
18.68
HIGH
18.79
LOW
18.62
VOLUME
76.87K
TURNOVER
--
52 WEEK HIGH
21.63
52 WEEK LOW
16.91
MARKET CAP
898.67M
P/E (TTM)
88.67
1D
5D
1M
3M
1Y
5Y
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 7.7% over the past three months, it is easy to disregard Amphastar Pharmaceuticals (NASDAQ:AMPH...
Simply Wall St. · 09/14 10:30
Amphastar Pharmaceuticals to Present at the Wells Fargo 2021 Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinic...
ACCESSWIRE · 09/02 20:05
Insider Trends: Insider Disposition Eases Back 90-Day Buy Trend at Amphastar Pharmaceuticals
MT Newswires · 08/17 16:32
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
Zacks.com · 08/17 15:04
Amphastar Pharmaceuticals (AMPH) Meets Q2 Earnings Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of 0.00% and 0.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/09 22:45
Amphastar Pharmaceuticals Q2 Adj. EPS $0.21, Inline, Sales $101.70M Miss $101.78M Estimate
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is a 31.25 percent increase over earnings of $0.16 per share from the same period last
Benzinga · 08/09 20:33
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021
7 Million for the Three Months Ended June 30, 2021RANCHO CUCAMONGA, CA / ACCESSWIRE / August 9, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2021.
ACCESSWIRE · 08/09 20:05
Amphastar Pharmaceuticals Reports Higher Q2 Results
MT Newswires · 08/09 16:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMPH. Analyze the recent business situations of Amphastar Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMPH stock price target is 22.75 with a high estimate of 25.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 194
Institutional Holdings: 30.93M
% Owned: 64.39%
Shares Outstanding: 48.03M
TypeInstitutionsShares
Increased
52
1.47M
New
27
1.19M
Decreased
43
897.52K
Sold Out
17
590.94K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Chief Operating Officer/Director
Mary Luo
President/Chief Executive Officer/Chief Scientific Officer/Director
Jack Zhang
Chief Financial Officer/Senior Vice President/Treasurer
William Peters
Executive Vice President/Director of Sales/Director of Marketing/Secretary
Jacob Liawatidewi
Executive Vice President
Rong Zhou
Lead Director/Independent Director
Richard Prins
Director
Diane Gerst
Independent Director
Richard Koo
Independent Director
Howard Lee
Independent Director
Floyd Petersen
Independent Director
Michael Zasloff
No Data
  • All
  • Financials
  • Insiders
More
About AMPH
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API, products. It manufactures and sells over 20 products. It operates through two segments: finished pharmaceutical products and API products. It marketed products include Primatene Mist, Enoxaparin, Glucagon for Injection Emergency Kit, Naloxone and Other finished pharmaceutical products. Primatene Mist, an over-the-counter epinephrine inhalation product, is indicated for the temporary relief of mild symptoms of intermittent asthma. Enoxaparin is an injectable form of low molecular weight heparin that is used as an anticoagulant, which is indicated for multiple indications, including the prevention and treatment of deep vein thrombosis. Glucagon for injection is a difficult to manufacture injectable product.

Webull offers kinds of Amphastar Pharmaceuticals Inc stock information, including NASDAQ:AMPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMPH stock methods without spending real money on the virtual paper trading platform.